Pharmaceutical Composition Comprising Ruxolitinib
A solid oral formulation of roxolitinib with hydroxypropyl cellulose and specific excipients addresses solubility and stability issues, achieving enhanced solubility and stability, with improved dissolution rates and extended shelf life.
Patent Information
- Application Number
- SA1120256746
- Authority / Receiving Office
- SA · SA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-15
- Filing Date
- 2025-09-14
- Publication Date
- 2026-10-05
AI Technical Summary
Existing solid oral pharmaceutical formulations of roxolitinib, particularly in its free base form, face challenges in achieving sufficient chemical stability and solubility, which are critical for maintaining drug quality and shelf life.
Formulating roxolitinib in a solid oral dosage form with a water-soluble polymer, such as hydroxypropyl cellulose, to enhance solubility and stability, while excluding certain polymers that may negatively affect these properties, and using specific excipients like microcrystalline cellulose and lactose monohydrate to improve mechanical strength and bulk density.
The formulation significantly enhances the solubility and chemical stability of roxolitinib, ensuring a shelf life of up to five years under specified conditions, with improved dissolution rates across various pH levels and reduced impurity formation during storage.
Abstract
Description
As mentioned above, solid oral pharmaceutical formulations are relatively stable with respect to the chemical stability of roxolitinib. In this context, the term "stability" refers to the definition established by the Arbeitsgemeinschaft für pharmazeutische Verfahrenstechnik (APV), which states that "stability" means the quality of the drug according to specifications until the end of its shelf life as defined by the manufacturer. Therefore, drug quality is determined by the content and purity of the active ingredient, as well as its sensory, physical, chemical, and microbiological properties. The content of the active ingredient until the end of the shelf life should not fall below 90% of the declared value. The pharmaceutical formulation according to this invention should preferably have, at a temperature of 30°C ± 2°C and relative humidity of 65% ± 5% (see Committee for Proprietary Medicinal Products (CPMP), "Guideline on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products", CPMP / QWP / 122 / 02, rev 1 corr of December 17), a stability or shelf life of not less than one year, preferably two years, better still three years, better still three and a half years, better still four years, better still four and a half years, and most preferably five years. Furthermore, the pharmaceutical formulation, according to this invention, should preferably have, at a temperature of 30°C ± 2°C and a relative humidity of 65% ± 5% (see Committee for Proprietary Medicinal Products (CPMP), "Guideline on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products", CPMP / QWP / 122 / 02, rev 1 corr of December 17, 2003), a stability or shelf life of up to one year, preferably two years, preferably three years, preferably three and a half years, preferably four years, preferably four and a half years, and most preferably five years. As mentioned above, the present invention relates to a solid oral pharmaceutical formulation containing ruxolitinib as the active pharmaceutical ingredient, where ruxolitinib is present in its free base form. This means that all ruxolitinib in the formulation is in its free base form. The pharmaceutical formulation may be formulated according to the present invention for the immediate, modified, metered, sustained, prolonged, extended, or delayed release of roxolitinib. However, according to one of the preferred models of the present invention, the pharmaceutical formulation is immediate-release. Pharmaceutical formulations of immediate, modified, metered, sustained, prolonged, extended, or delayed release, and their preparation, are well known in the prior art and belong to the general knowledge of the competent person. In addition to a free base of roxolitinib, the pharmaceutical formulation under this invention may include one or more additional active pharmaceutical ingredients. However, under another preferred model of the present invention, roxolitinib is the only active pharmaceutical ingredient in the formulation. Specifically, the solubility of the roxolitinib free base can be improved if the formulation includes a water-soluble polymer. Therefore, according to an additional preferred model for the present invention, the pharmaceutical formulation contains the roxolitinib free base in combination with a water-soluble polymer. According to one of the preferred models for the present invention, water-soluble polymers are defined as those in which at least 1.0 g and preferably 2.0 g dissolve in 100 g of water at 25 °C and pH 7. The solubility rate of roxolitinib's free base can also be improved if the innovative formulation includes a water-soluble polymer in which the roxolitinib free base is dispersed. Therefore, according to an additional preferred model based on the present invention, the pharmaceutical formulation contains a roxolitinib free base dispersed in a water-soluble polymer. The solubility of the roxolitinib free base can be further improved if the innovative formulation includes a water-soluble polymer in which the roxolitinib free base is molecularly dispersed. Therefore, according to the preferred model in the present invention, the pharmaceutical formulation contains a roxolitinib free base molecularly dispersed in a water-soluble polymer. Furthermore, the solubility of the roxolitinib free base can be further improved if the innovative formulation contains the roxolitinib free base as a solid solution of roxolitinib free base in a water-soluble polymer. Therefore, according to the additional preferred model described in the present invention, the pharmaceutical formulation contains the roxolitinib free base as a solid solution of roxolitinib free base in a water-soluble polymer. According to another preferred model of the present invention, the innovative pharmaceutical formulation is prepared by a process that includes the following steps - Dissolving the free base of roxolitinib and a water-soluble polymer in a solvent to obtain a solution, and - Remove the solvent from the aforementioned solution. The innovative pharmaceutical formulation prepared using the aforementioned steps ensures a sufficient solubility of the roxolitinib free base from the formulation. In this context, organic solvents such as alcohols, water, or mixtures thereof can be used as solvents. For example, the aforementioned roxolitinib free base / water-soluble polymer solution can be obtained by dissolving the roxolitinib free base in ethanol, or by dissolving the water-soluble polymer in water, and then by mixing the resulting solutions into a final solution from which the solvent has been removed. According to another preferred model of the present invention, the water-soluble polymer is chosen from the group consisting of hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC), methyl cellulose (MC), hydroxyethyl methyl cellulose (HEMC), sodium carboxymethyl cellulose (CMC), hydroxyethyl carboxymethyl cellulose (HECMC), hydroxypropyl carboxymethyl cellulose (HPCMC), hydroxypropyl methyl cellulose acetate succinate, cellulose acetate trimellitate, acrylic and methacrylic polymers and their copolymers, methacrylic acid-methyl methacrylate copolymer, polyaminoalkyl methacrylate-methacrylate esters copolymer, dimethylaminoethyl methacrylate-butyl methacrylate-methyl methacrylate copolymer, and vinyl polymer. Pyrrolidone-vinyl acetate copolymer, methyl vinyl ether-maleic acid copolymer, polyethylene glycol-caprolactam-vinylpyrrolidone copolymer.The aforementioned water-soluble polymers can significantly increase the solubility rate of the free base of roxolitinib and can also act as a binder to provide the innovative pharmaceutical formulation with sufficient chemical stability. Specifically, hydroxypropyl cellulose (HPC) is the preferred water-soluble polymer under the present invention. In another preferred model, the pharmaceutical formulation is free of cellulose ester derivatives, nitrogenous polymers, and polymers with unsaturated bonds. The use of these polymers is not recommended, as they may negatively affect solubility and stability. According to another preferred model of the present invention, the weight ratio of the free base of roxolitinib and the water-soluble polymer in the formulation ranges from 2.0 to 0.1. According to another preferred model of the present invention, the pharmaceutical formulation also includes at least one pharmaceutically acceptable excipient that may be chosen, for example, from thinning agents, binders, dispersants, lubricants, and lubricants. Diluents are fillers used to increase the bulk density of a pharmaceutical formulation. By combining a diluent with the free base of roxolitinib, the final product is given sufficient weight and volume to facilitate production and administration. The pharmaceutical formulation according to the present invention should preferably contain at least one diluent. The diluent should ideally be used in amounts ranging from 15% to 95%, preferably 50% to 90% by weight, depending on the total weight of the formulation. Suitable examples of diluents to be used in accordance with the present invention include microcrystalline cellulose and lactose monohydrate. In one of the preferred models of the present invention, the diluent materials to be used are microcrystalline cellulose, lactose monohydrate, or mixtures thereof. The pharmaceutical formulation created under the present invention may also contain a binder. Binders ensure that pharmaceutical formulations can be created with the desired or required mechanical strength. Binders suitable for use under the present invention include povidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and sodium carboxymethyl cellulose. Binders should ideally be used in quantities ranging from 1% to 20% by weight, depending on the total weight of the formulation. As previously explained, the water-soluble polymer that can be contained in the innovative formulation can indeed have the function of a bonding agent. The pharmaceutical formulation under the present invention may optionally contain a dispersant. Dispersants are added to the formulation to promote the disintegration of the formulation into smaller fragments in an aqueous environment, thereby increasing the available surface area and promoting the rapid release of the active pharmaceutical ingredient. Suitable examples of dispersants to be used under the present invention include crospovidone, sodium starch glycolate, croscarmellose sodium, and mixtures thereof. Dispersants are preferred in amounts ranging from 1% to 25% by weight, depending on the total weight of the formulation. The preferred dispersant in the context of the present invention is sodium starch glycolate, with a preferred amount ranging from 1% to 5% by weight, depending on the total weight of the formulation. The pharmaceutical formulation described in the present invention may also contain a lubricant. Lubricants are generally used to reduce sliding friction, specifically at the interface between the mixture to be encapsulated and the dosing device of the encapsulating machine. Suitable lubricants for use in the present invention include magnesium stearate, stearic acid, glyceryl behenate, hydrogenated vegetable oil, talc, and glyceryl fumarate. Magnesium stearate is the preferred lubricant in the present invention. The preferred lubricant is 0.01% to 5% by weight of the formulation, with 0.01% to 0.05% by weight being optimal. The pharmaceutical formulation, as per the invention, may also contain a lubricant. Lubricants improve product flow by reducing friction between particulate materials. A suitable example is colloidal silicon dioxide. The pharmaceutical formulation, according to the present invention, is a solid substance and can therefore be, for example, in the form of a tablet, capsule, pill, granule, powder, and so on. However, according to one of the preferred models of the present invention, the pharmaceutical formulation is a tablet, specifically a film-free tablet. According to another preferred model of the present invention, the pharmaceutical formulation is povidone-free. This means that the formulation contains less than 0.1% by weight, preferably less than 0.01% by weight, povidone, and ideally, is completely povidone-free based on the total weight of the formulation. The absence of povidone in the formulation has also been found to improve the stability of the free base of ruxolitinib. According to another preferred model of the present invention, the pharmaceutical formulation contains a free base of roxolitinib in the range of 2 mg to 50 mg, specifically 5 mg, 10 mg, 15 mg, 20 mg or 25 mg of the free base of roxolitinib. The present invention also relates to a process for preparing a pharmaceutical formulation in accordance with the invention, which includes the following steps: a) Dissolve the free base of roxolitinib in a solvent, preferably alcohol, water or a mixture of both, to obtain a solution; b) Apply the aforementioned solution to at least one pharmaceutically acceptable excipient to obtain a moisturizing excipient; c) Drying the moisturizing excipient. According to one of the preferred models of the process according to the present invention, step A) also involves dissolving a water-soluble polymer in the solvent or solution. According to another preferred model of the process according to the present invention, the process in step b) involves the granulation of at least one pharmaceutically acceptable excipient to obtain a granule by means of the solution of step a) as a granulating liquid, and is characterized by step c) involving the drying of the resulting granule. According to another preferred model of the process according to the present invention in step b) the solution is applied to a fluidized layer of at least one pharmaceutically acceptable excipient at an elevated temperature, preferably at a temperature of 30°C to 50°C. Comparative Example 1 As a comparative example, Jakavi® tablets marketed at concentrations of 5, 10, 15, 20 and (20 + 5) mg were analyzed. According to the summary of properties of the Jakavi® product, the tablets contain roxolitinib in the form of the phosphate salt (e.g., the 20 mg tablets contain 20 mg of roxolitinib (free base) in the form of the phosphate salt) in addition to microcrystalline cellulose, magnesium stearate, colloidal anhydrous silica, sodium starch glycolate, povidone, hydroxypropyl cellulose and lactose monohydrate as pharmaceutical excipients. The dissolution rate of roxolitinib in vitro was analyzed for the tablets mentioned using the stirrer method (device 2) in accordance with the provisions of the European Pharmacopoeia (European Pharmacopoeia, Class VIII, Annex VII, 2.9.3 Test of dissolution of solid oral dose images), pp. 7367-7375 (German version)) at a speed of 50 rpm in a buffer solution of 900 mL at 37 °C with pH values of 1.2 (hydrochloric acid solution), 4.5 (sodium acetate buffer solution) and 6.8 (phosphoric acid solution). The results of the dissolution tests are shown in the following tables, where infinite data correspond to stirring at 150 rpm for 15 minutes after 45 minutes. Table 1: Average dissolution values of Jakavi® 5 mg tablets at different pH values (Volume 900 ml; 50 rpm; N=3 (number of tablets); values in brackets are RSD [%] (relative standard deviation)) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 86(13.0) 73(0.8) 56(10.2) 10 95(4.8) 89(1.1) 78(0.7) 15 97(3.1) 93(1.1) 85(0.7) 20 98(2.6) 94(1.1) 88(1.7) 30 99(1.5) 95(1.1) 90(2.6) 45 100(1.0) 96(1.2) 91(2.5) Infinite 101(0.6) 101(0.0) 100(0.0) Table 2: Average dissolution values of Jakavi® 10 mg tablets at different pH values (Volume 900 ml; 50 rpm; N=3 (number of tablets); values in brackets are RSD [%] (relative standard deviation)) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 77(5.4) 70(3.6) 67(3.1) 10 87(2.4) 86(0.0) 84(6.5) 15 90(1.3) 89(1.1) 89(7.3) 20 92(1.1) 91(1.7) 91(7.2) 30 95(0.6) 92(1.7) 93(6.6) 45 97(0.6) 93(1.6) 94(6.4) Infinite 102(1.0) 100(1.2) 101(1.5) Table 3: Average dissolution values of Jakavi® 15 mg tablets at different pH values (Volume 900 ml; 50 rpm; N=3 (number of tablets); values in brackets are RSD [%] (relative standard deviation)) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 85(5.4) 74(6.1) 66(4.0) 10 92(1.7) 86(4.4) 82(2.5) 15 94(0.6) 88(3.6) 86(2.3) 20 95(0.6) 89(3.6) 88(1.7) 30 97(0.6) 90(3.6) 90(1.1) 45 98(0.6) 91(2.9) 91(1.7) Infinite 101(1.0) 98(0.6) 99(0.6) Table 4: Average dissolution values of Jakavi® 20 mg tablets at different pH values (Volume 900 mL; 50 rpm; N=3 (number of tablets); values in brackets are RSD [%] (relative standard deviation)) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 83(2.5) 70(3.0) 59(2.6) 10 90(1.9) 81(2.6) 77(3.9) 15 92(1.9) 83(3.0) 82(4.3) 20 93(2.2) 85(2.5) 85(4.1) 30 94(2.2) 86(2.4) 86(4.7) 45 96(2.6) 87(2.4) 88(4.5) Infinite 100(1.5) 96(1.0) 98(0.0) Table 5: Average dissolution values of Jakavi® 20 mg + 5 mg tablets (one 20 mg Jakavi® tablet and one 5 mg Jakavi® tablet) at different pH values (Volume 900 mL; 50 rpm; N=3 (number of tablet pairs); values in brackets are RSD [%] (relative standard deviation) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 85(9.3) 59(3.5) 58(4.3) 10 91(7.3) 72(2.1) 72(2.1) 15 93(6.2) 76(2.0) 76(2.0) 20 95(5.8) 78(1.5) 77(2.0) 30 96(5.1) 80(2.2) 80(2.6) 45 98(4.8) 82(2.5) 82(2.4) Infinite 104(2.8) 92(1.3) 92(1.1) Furthermore, the stability of Jakavi® 20 mg tablets was verified by examining the chemical stability of roxolitinib, specifically the original value immediately after purchase and also after storage in aluminum-aluminum cartons under accelerated conditions of 40°C / 75% RH / 15 days or 60°C / 75% RH / 15 days. The stability study results are shown in Table 6 below. Table 6: Stability of Jakavi® 20 mg tablets Storage condition: Total impurities / % Original 0.2 40°C / 75% humidity / 15 days 0.22 60°C / 75% humidity / 15 days 0.62 The data in Table 6 were determined by high-performance liquid chromatography (HPLC) and evaluated using the area normalization method. HPLC was performed using the following parameters: High-performance liquid chromatography, chromatographic conditions: Column: Zorbax Eclipse XDB C18, 3.5 micrometers (150*4.6 mm); Mobile phase: A. Water, B. Acetonitrile, Linear sequential filtration (below) Time (minutes) A(%) B(%) 0.0 85 15 4.0 70 30 12.0 50 50 Detection wavelength: 220 nm; Flow rate: 1.0 ml / min; Column temperature: 30°C; Test solvent: Acetonitrile - Water (1:1); Test concentration: 250 micrograms / ml Example 1 Roxolitinib tablets were prepared as a single prototype of the solid oral pharmaceutical formulation according to the invention with the following formulation: Disc component [% by weight] Roxolitinib free base (dihydrate) 3.4 Microcrystalline cellulose (PH101) 39.4 Lactose monohydrate 50.5 Sodium carboxymethyl starch (a) 3.0 Hydroxypropyl cellulose (HPC-L, low substitution) 2.5 colloidal silica 0.9 Magnesium stearate 0.3 Water (not present in the final product) (22) Ethanol (not present in the final product) (14.8) Total 100 These tablets (containing 5 mg, 10 mg, 15 mg, and 20 mg of the free base of roxolitinib) were prepared according to the procedure described in the present invention. The preparation of tablets containing 20 mg of the free base of roxolitinib is described below. A granulation fluid was prepared by dissolving 27.94 g of the free base of roxolitinib (dihydrate) in 100 g of 95% ethanol to obtain a first solution, by dissolving 20 g of hydroxypropyl cellulose in 150 g of purified water to obtain a second solution, and by mixing the first and second solutions mentioned above to obtain the granulation fluid in the form of a solution. The granulation fluid was sprayed onto a fluidized bed of microcrystalline cellulose, lactose monohydrate, and sodium carboxymethyl starch at an atomic pressure of 3.0 bar and an inlet air temperature of 40°C. After spraying the granulation fluid, the tubes were washed with 50 g of a 40% ethanol / water solution, which was also sprayed onto the fluidized bed. The resulting granules were dried in the fluidized bed at a temperature of 40°C to an LOD of 2.3%. The dried granules are mixed with colloidal silica, ground, sieved, coated with magnesium stearate and pressed into tablets that have the same shape and hardness as the example tablets. The dissolution rate of roxolitinib in the laboratory from the tablets mentioned in the invention was determined in accordance with the terms and conditions stated in Clause "Comparative Example 1". The results of the dissolution tests are shown in the following tables 7-11: Table 7: Average dissolution values of 5 mg tablets of roxolitinib free base at different pH values (Volume 900 mL; 50 rpm; N=3 (number of tablets); values in brackets are RSD [%] (relative standard deviation)) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 100(4.6) 87(2.2) 87(2.6) 10 105(1.9) 102(2.5) 103(0.9) 15 106(1.4) 104(2.5) 106(0.5) 20 106(1.1) 105(1.6) 106(0.9) 30 106(1.1) 106(0.5) 107(1.1) 45 106(1.1) 106(0.5) 107(1.1) Infinite 106(1.4) 108(1.8) 107(0.9) Table 8: Average dissolution values of 10 mg tablets of the free base of roxolitinib at different pH values (Volume 900 mL; 50 rpm; N=3 (number of tablets); values in brackets are RSD [%] (relative standard deviation)) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 93(0.6) 88(1.1) 84(2.4) 10 101(0.6) 98(1.5) 100(1.0) 15 102(1.1) 99(1.5) 102(1.1) 20 103(0.9) 99(1.5) 102(0.6) 30 103(1.4) 100(1.0) 103(0.5) 45 103(1.4) 100(1.0) 103(0.5) Infinite 103(1.4) 101(2.0) 103(0.0) Table 9: Average dissolution values of 15 mg tablets of the free base of roxolitinib at different pH values (Volume 900 mL; 50 rpm; N=3 (number of tablets); values in brackets are RSD [%] (relative standard deviation)) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 92(4.4) 92(1.6) 87(5.3) 10 100(3.4) 100(1.0) 100(2.5) 15 101(3.1) 101(1.1) 102(1.9) 20 103(2.9) 102(1.0) 103(2.0) 30 103(2.5) 103(0.5) 103(1.4) 45 104(1.9) 104(0.5) 103(1.9) Infinite 105(1.9) 104(0.9) 105(0.5) Table 10: Average dissolution values of 20 mg tablets of the free base of roxolitinib at different pH values (Volume 900 mL; 50 rpm; N=3 (number of tablets); values in brackets are RSD [%] (relative standard deviation)) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 95(4.3) 91(1.1) 86(1.3) 10 101(1.5) 100(2.6) 96(1.2) 15 102(0.0) 101(2.5) 98(1.1) 20 103(0.5) 102(2.9) 98(1.1) 30 104(0.5) 102(2.4) 99(1.1) 45 104(0.5) 102(2.9) 100(1.0) Infinite 104(0.9) 104(2.0) 102(0.6) Table 11: Average dissolution values of 25 mg tablets of the free base of roxolitinib at different pH values (Volume 900 mL; 50 rpm; N=3 (number of tablet pairs); values in brackets are RSD [%] (relative standard deviation) Time pH 1.2 pH 4.5 pH 6.8 [minute] 5 94(3.8) 88(4.2) 85(3.5) 10 98(2.3) 99(1.5) 98(2.0) 15 99(1.5) 100(1.0) 100(2.0) 20 100(1.5) 101(0.6) 100(1.9) 30 100(1.0) 101(0.6) 101(2.4) 45 101(1.1) 102(0.6) 101(1.9) Infinite 102(1.1) 102(0.0) 103(0.9) Comparing the dissolution data for Comparative Example 1 with the dissolution data for the present example according to the invention shows that the dissolution rate of the formulation according to the invention is much higher at all verified pH values than that of the corresponding previous comparative examples. Furthermore, the stability of the tablets was verified according to the present example 1, considering the chemical stability of roxolitinib, specifically the original value immediately after tablet preparation and also after storage in aluminum-aluminum cartons under accelerated conditions at 40°C / 75% RH / 15 days or at 60°C / 75% RH / 15 days. The stability study results were determined by applying the peak area obtained by HPLC and are shown in Table 12 below. Table 12: Stability of 20 mg of roxolitinib free base preparation Storage status: Total impurities [%] Original 0.03 40°C / 75% humidity / 15 days 0.05 60°C / 75% humidity / 15 days 0.27 The data were identified in Table 12 and evaluated using the methods described in the previous chapter, "Comparative Example 1". Comparing the stability data for Comparative Example 1 with the stability data for Example 1 clearly shows that roxolitinib exhibits significantly higher stability in the formulation according to the current invention. This comparison is illustrated in Table 13 below. Table 13: Comparison of stability data Jakavi® 20 mg tablets, free base of roxolitinib 20 mg Total storage status: Impurities [%] Total impurities [%] Original 0.2 0.02 40°C / 75% humidity / 15 days 0.22 0.05 60°C / 75% humidity / 15 days 0.62 0.27
Claims
1. A solid oral formulation containing roxolitinib as the active pharmaceutical ingredient, where roxolitinib is present as its free base.
2. The formulation, according to protection element 1, is characterized as an immediate-release formulation.
3. The formulation, according to one of the above protection elements, is characterized by roxolitinib being the sole active pharmaceutical ingredient.
4. The formulation, according to one of the above protection elements, is characterized by containing the free base of roxolitinib in a mixture with a water-soluble polymer.
5. The formulation, according to one of the above protection elements, is characterized by containing the free base of roxolitinib dispersed in a water-soluble polymer.
6. The formulation, according to one of the above protection elements, is characterized by containing the free base of roxolitinib molecularly dispersed in a water-soluble polymer. 7.The pharmaceutical formulation, according to one of the aforementioned safeguards, is characterized by the fact that the formulation contains the free base of roxolitinib as a solid solution of the free base of roxolitinib in a water-soluble polymer.
8. The pharmaceutical formulation, according to one of the aforementioned safeguards, is characterized by the fact that the formulation is prepared by a process that includes the following steps: dissolving the free base of roxolitinib and a water-soluble polymer in a solvent to obtain a solution, and removing the solvent from said solution.
9. The pharmaceutical formulation, according to safeguards 4 to 8, is characterized by the fact that the water-soluble polymer is chosen from the group consisting of hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC), methyl cellulose (MC), hydroxyethyl methyl cellulose (HEMC), and sodium carboxymethyl cellulose (CMC).Hydroxyethyl carboxymethyl cellulose (HECMC), hydroxypropyl carboxymethyl cellulose (HPCMC), hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimelate, acrylic and methacrylic polymers and their copolymers, methacrylic acid-methyl methacrylate copolymer, polyaminoalkyl methacrylate-methacrylate esters copolymer, dimethylaminoethyl methacrylate-butyl methacrylate-methyl methacrylate copolymer, vinylpyrrolidone-phenyl acetate copolymer, methylphenyl ether-maleic acid copolymer, polyethylene glycol-caprolactam-phenylpyrrolidone copolymer.
10. A pharmaceutical formulation, in accordance with one of the aforementioned safeguards, is characterized by the inclusion of at least one pharmacologically acceptable excipient.
11. The pharmaceutical formulation, according to one of the aforementioned protection elements, is characterized by being a tablet.
12. The pharmaceutical formulation, according to one of the aforementioned protection elements, is characterized by being povidone-free. 13.A pharmaceutical formulation, according to one of the aforementioned safeguards, is characterized by containing a free base of roxolitinib in the range of 2 mg to 50 mg.
14. A pharmaceutical formulation, according to one of the aforementioned safeguards, is characterized by containing 5 mg, 10 mg, 15 mg, 20 mg, or 25 mg of the free base of roxolitinib.
15. A process for preparing a pharmaceutical formulation according to one of the aforementioned safeguards includes the following steps: d) dissolving a free base of roxolitinib in a solvent to obtain a solution; e) applying the said solution to at least one pharmacologically acceptable excipient to obtain a hydrated excipient; and f) drying the hydrated excipient.
16. A process, according to one of the aforementioned safeguards, is characterized by step a) also involving the dissolution of a water-soluble polymer in the solvent or solution.
17. The process, according to one of the aforementioned safeguards, is characterized by the fact that step B involves the granulation of at least one pharmaceutically acceptable excipient to obtain a granule using the solution from step A as a granulating liquid, and that step C involves drying the resulting granule. 18.The process, according to one of the previous protection elements, is characterized by the fact that in step b) the solution is applied to a fluidized layer of at least one pharmaceutically acceptable excipient at a high temperature.
